glp-1 agonist cardiovascular outcomes The effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 Receptor Agonists in the

Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes

But they can help you reach a better weight baseline

1 This led researchers to further investigate the link between gastric hormones and insulin release

A clinical trial found that in patients with MCI, a 32-week trial of slow-release exenatide had no beneficial effect on cognitive performance (Vadini et al., 2020)

In rats, infusion of GRP stimulates the secretion of GLP-1 while administration of the GRP antagonist BW10 blocks GLP-1 secretion when fat is directly administered into the duodenum [339]

Comparing the Two: GLP-1 Medications vs Bariatric Surgery Both GLP-1 therapies and bariatric surgery contribute to weight reduction, but they operate through very different mechanisms and produce distinctly different long-term outcomes